It is a challenge to detect malignancies in biliary strictures. Various sampling methods are available to increase diagnostic yield, but these require additional procedure time and expertise. We evaluated the combined accuracy of fluorescence in situ hybridization (FISH) and polymerase chain reaction-based DNA mutation profiling (MP) of specimens collected using standard brush techniques.
D
espite advances in therapies to treat biliary disease, diagnosing malignancy in biliary strictures remains challenging. 1, 2 Multiple procedural or imaging modalities and sampling techniques have been used to evaluate strictures, with biliary brushings for routine cytology typically obtained during endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography being the first-line approach. 3 Because the specificity of cytology is nearly 100%, a positive result can be trusted to rule in the presence of malignancy. However, brush cytology has poor sensitivity for malignancy, ranging from 5% to 40%, making cytology alone inadequate to rule out the presence of malignancy. 4, 5 Although additional sampling methods such as fluoroscopy-assisted biopsies or cholangioscopic biopsies can increase diagnostic accuracy, they require added cost, procedural time, and significant expertise. As treatments for biliary cancer continue to lead to better outcomes, 6, 7 it is increasingly important to diagnose strictures accurately for effective patient management. A means to help diagnose strictures from routine brush procedures, without the need for additional devices or endoscopic training, carry significant potential for possible widespread utilization.
Previous studies have described the utility of fluorescence in situ hybridization (FISH) in diagnosing malignancy in biliary disease. 4, [8] [9] [10] [11] [12] FISH uses fluorescence-labeled probes to evaluate the presence of chromosomal abnormalities in cells obtained via routine biliary brushings. Polysomy of chromosomes 3, 7, and 17 centromeric regions or 1q21, 7p12, or 8q24 chromosomal regions have proven the most useful in aiding diagnosis. 4, 9, 10, 13 Detection of homozygous or heterozygous deletion of the 9p21 locus (p16) also can help increase the diagnostic yield and accuracy of biliary malignancy. 8 However, this detection method relies on the presence of intact neoplastic cells in the brushing specimen.
Recent studies have shown value in diagnosing pancreaticobiliary malignancy using polymerase chain reaction (PCR)-based mutation analysis of DNA. 10, [14] [15] [16] Mutation profiling (MP) for KRAS oncogene mutations 10, [14] [15] [16] and tumor-suppressor gene loss-ofheterozygosity (LOH) mutations [14] [15] [16] have identified malignancies otherwise undetectable by cytology. Unlike cytology and FISH, MP can be performed on free DNA using residual preservative fluid that remains after cytocentrifugation of cells from biliary brush specimens. [14] [15] [16] Such fluid usually is discarded, with cell pellets reserved for cytology. Numerous studies have reported the high fidelity of extracellular DNA that surrounds cancer cells, with some suggesting that this DNA may be more representative of tumors than intracellular DNA. [17] [18] [19] [20] [21] [22] [23] [24] PCR-based DNA analysis of supernatant fluid could be of significant value when brush specimens have limited cellularity. [14] [15] [16] We aimed to understand the role PCR-based DNA analysis may play in diagnosing malignancy in patients with biliary strictures. We compared the diagnostic accuracy of cytology and FISH testing for malignancy with that of MP of free DNA in supernatant fluid obtained from the same patients. We also assessed the incremental value of MP and FISH in detecting malignancy when cytology of biliary strictures is negative or indeterminate.
Methods

Patient Selection
This study was approved by the Institutional Review Board of Columbia University (AAAL6503). A waiver of consent was obtained because molecular analysis was performed on discarded, de-identified medical waste collected during standard ERCP procedures. Consecutive patients who underwent ERCP between June 2012 and June 2014 at Columbia University Medical Center (New York, NY) for the evaluation of biliary strictures were included. Only patients who had 2 biliary brushings (1 for cytology and 1 for FISH) and had a final pathologic diagnosis of at least 12 months follow-up evaluation were included in the study. A stricture was designated as nonmalignant if at 12 months' follow-up repeat imaging, repeat procedure, or repeat laboratory testing was performed and these documented the resolution of the stricture or prior abnormalities. A diagnosis of malignant stricture was made with either subsequent biopsy or cytology specimens showing malignancy, final malignant pathology was obtained by surgery, or if the cause of death was biliary malignancy.
Specimen Collection
Samples were obtained by using 2 standard cytology brushes (Boston Scientific, Cambridge, MA). Samples were collected with at least 10 to-and-fro motions at the site of stricture for both cytology and FISH specimens. Cytology specimens always were taken from the first brush, and the second brush was used for FISH analysis. Each brush was placed into 15 mL of ThinPrep CytoLyt solution (Hologic, Marlborough, MA) and was transferred to the onsite laboratory within 24 hours. The cytocentrifugation supernatant fluid produced as a result of cytology and FISH testing then was sent to Interpace Diagnostics (formerly RedPath Integrated Pathology, Inc, Pittsburgh, PA) for DNA MP.
Cytology Testing and Analysis
Cytology specimens were analyzed by a cytologist as part of the standard clinical procedures at Columbia University Medical Center. Respective language in each cytology report was used to classify cases as "non-diagnostic," "no malignancy," "atypical," "suspicious," or "malignant." Test performance was assessed using malignant cells as a positive cytology result, where all other cytology classifications were considered negative for malignancy. Test performance also was assessed when either suspicious or malignant results were considered positive. Nondiagnostic cytology cases were those in which the cytology report indicated no diagnosis rendered or nondiagnostic as a result of accellularity.
Fluorescence In Situ Hybridization Testing and Analysis
FISH was performed by using the standard protocols and commercially available probes specific to centromeres of chromosomes 3 (chromosome enumeration probed [CEP] 3, orange), 7 (CEP 7, green), and 17 (CEP 17, aqua) in 1 hybridization and p16 (9p21, orange/ centromere 9, green) in the second hybridization (Supplementary Materials). An additional hybridization probe (Urovysion; Abbott Molecular, Des Plaines, IL) consisting of CEP 3 (orange), CEP 7 (green), CEP 17 (aqua), and 9p21 (p16, gold) was used in some cases. If a specimen was positive for either polysomy or a p16 deletion, the test was considered positive. To be considered negative, polysomy and p16 deletion was required to be absent. Specimens with an insufficient amount of cells for FISH testing were considered nondiagnostic by FISH. The nondiagnostic cases were treated as negative for the test performance analysis.
DNA Mutation Profiling Testing and Analysis
A clinically validated panel was used in MP testing. [14] [15] [16] The panel included DNA markers for KRAS oncogene mutations and tumor-suppressor gene LOH mutations at 10 genomic loci (known commercially as PathFinderTG -Biliary). Interpace Diagnostic Corporation provided financial research-related support to Columbia University Medical Center for the processing, mailing, and analysis of these specimens. The presence or absence of KRAS oncogene mutations were examined in codons 12 and 13 (see Supplementary Materials and Methods). Tumor-suppressor gene LOH mutations were assessed using the presence or absence of allelic imbalance at the following 10 genomic loci (tumor-suppressor gene) via capillary gel electrophoresis: 1p (CMM1, Lmyc), 3p (VHL, OGG1), 5q (MCC, APC), 9p (CDKN2A, CDKN2B), 10q (PTEN, MXI1), 17p (TP53), 17q (NME1, RNF34), 18q (SMAD4, DCC), 21q (TFF1, PSEN2), and 22q (NF2) (see Supplementary Materials and Methods).
Specimens that contained sufficient amounts of amplifiable DNA were categorized as positive for malignancy by MP based on the presence of at least 1 mutation in the form of KRAS point mutation or tumor-suppressor gene panel allelic imbalance (LOH) mutation in either supernatant fluid DNA. Specimens with insufficient amounts of amplifiable DNA were categorized as nondiagnostic by MP and treated as negative for the test performance analysis, as were those that had sufficient amounts of DNA and lacked any detectable mutations.
Statistical Analysis
We aimed to enroll 100 consecutive patients with biliary strictures based on sample size calculations (see Supplementary Materials and Methods). Overall accuracy, sensitivity, and specificity for each test and test combinations were calculated. The exact binomial test was used to compare the sensitivities and specificities of both individual and combination tests with malignant cytology results. In addition, the combinations of tests were compared for performance across the locations of the brushing relative to the liver (ie, proximal vs distal) and among types of cancer (eg, pancreatic vs cholangiocarcinoma) using the Fisher exact test.
Results
A total of 907 ERCPs were performed for biliary strictures or obstruction during the study period ( Figure 1 ). We reasoned to exclude patients with an obvious mass on endoscopic ultrasound, a positive rapid on-site evaluation of cytology, or stone disease. Patients who underwent concurrent endoscopic ultrasound were included when they lacked a mass and had a fine-needle aspiration of an abnormal bile duct wall or area in the head of pancreas (n ¼ 107). Seven patients were excluded from analysis because of incorrect sample processing for FISH or MP testing, uncertain final pathology diagnosis, or confirmation of cancer other than cholangiocarcinoma or pancreatic cancer. Of patients included in the analysis (n ¼ 100), 41% (41 of 100) had malignant strictures and 59% (59 of 100) had nonmalignant strictures. Table 1 shows the demographics of the malignant and nonmalignant strictures. Patients who had malignant strictures were significantly older than those who had nonmalignant strictures. The proportion of strictures proximal (Bismuth-Corlette type II-IV) or distal (Bismuth-Corlette type I or common bile duct stricture) was similar among nonmalignant and malignant cases, with most patients having strictures that were distal to the common hepatic duct. Primary sclerosing cholangitis (PSC) was present concurrently in 12% of all malignant cases, representing roughly a third of all cholangiocarcinomas.
Two of 100 cases did not have cytology reports and were treated as negative for malignancy. Ninety-eight of 100 cases had cytology reports available for classification of results into 1 of 4 category thresholds for malignancy based on the language in the cytology report: nondiagnostic (n ¼ 9 of 98), no malignancy (n ¼ 32 of 98), atypical (n ¼ 39 of 98), suspicious (n ¼ 5 of 98), or malignant (n ¼ 13 of 98). Cytology had high specificity (100%) but low sensitivity (32%) for malignancy when malignant cells were required to deem a case malignant and all other cytology categories were treated as negative for malignancy (Table 2) . Sensitivity improved when cells with suspicious features also were considered sufficient for a malignant diagnosis ( Table 2 ). The inclusion of atypical cells as well as suspicious and malignant cells as positive for malignancy further improved the sensitivity to 78%, but the specificity and accuracy decreased significantly to 58% and 66%, respectively (P < .001). Because of the high false-positive rate, atypical cells were treated as negative for malignancy in all subsequent analyses.
Analysis of FISH accuracy included the presence of either polysomy alone or polysomy (FISH) or p16 deletion (FISH p16 ). PCR-based mutation analysis included the presence of tumor-suppressor gene LOH mutations at 10 genomic loci or KRAS oncogene mutations (ie, MP) and the presence of KRAS oncogene mutation alone (ie, KRAS). Inclusion of the p16 marker in FISH (FISH p16 ) or the tumor-suppressor LOH panel in MP increased sensitivity to 41% and 39%, respectively. Neither FISH p16 nor MP alone had a significantly higher sensitivity than cytology (Table 2) . Notably, the specificity of each test was 100%. Of the cases with positive MP results, there were 5 of 16 with a tumor-suppressor panel LOH mutation, 4 of 16 with a KRAS mutation, and 7 of 16 with both a KRAS and LOH mutation (data not shown).
Given the high specificity but suboptimal sensitivity of each individual diagnostic test, the combination of cytology results with either FISH p16 or MP testing was examined (Table 2) . By using definitively malignant cytology or positive FISH p16 showed improved sensitivity compared with malignant cytology results alone, which held true when suspicious cells were used with FISH p16 to diagnose malignancy. Similarly, using malignant or suspicious cytology or positive MP as a positive result for malignancy improved sensitivity. When a positive result from any of the 3 approaches (malignant cytology, FISH p16 , and MP) was used to rule in the presence of malignancy, sensitivity was improved further, compared with cytology alone (32% vs 73%; P < .0001) ( Table 2) . Moreover, the combination of all 3 approaches improved sensitivity relative to the combination of malignant cytology with either FISH p16 or MP approaches (both P < .0039).
The added value of MP and FISH p16 was examined in greater depth for cases that had indeterminate cytology results. In the 87% of cases indeterminate for malignancy by cytology, results were as follows: (1) (Table 3) .
Test performance among proximal (n ¼ 31) vs distal (n ¼ 69) stricture locations and type of cancer (pancreatic [n ¼ 13] vs cholangiocarcinoma [n ¼ 22]) was assessed using the same individual tests or combinations of tests (data not shown). The sensitivities of using malignant cytology, FISH p16 , and/or MP to diagnose malignancy in distal compared with proximal strictures were not statistically different (P ¼ 1.000). The sensitivities of using malignant cytology, FISH p16 , and/or MP to diagnose malignancy in pancreatic cancer compared with cholangiocarcinoma also were not statistically different (P ¼ .4437). Use of a combination of all 3 modalities (cytology, FISH p16 , and MP) was the most accurate diagnostic approach for all stricture locations and malignancy types examined.
Discussion
Cytology testing of cells from biliary brushings has poor sensitivity for malignancy. [25] [26] [27] Studies have shown that DNA-based polysomy FISH testing of cells from brushings has higher sensitivity and comparable specificity with routine cytology. 8,9,27 As such, a combination a "Malignant" cytology language was used for sensitivity comparison in exact binomial test. b "Atypical," "suspicious," and "malignant" cytology language were considered positive cytology. c "Suspicious" and "malignant" cytology language were considered positive cytology. of cytology and FISH testing has been recommended to improve detection of malignancy. 8, 9, 13, 27 However, the sensitivity of this combination testing remains suboptimal, with cellularity of specimens a persistent limiting factor.
In a prospective cohort of consecutive patients undergoing ERCP for the diagnostic evaluation and treatment of biliary strictures, we report the added benefit of FISH and PCR-based DNA MP to ruling in malignancy in cases with negative or indeterminate cytology. MP and FISH testing can be performed on specimens obtained in current clinical practice and therefore do not require additional procedure time or expertise. We examined polysomy and p16 deletion using FISH analysis of cells and KRAS and tumorsuppressor LOH mutations using PCR-based MP analysis of free DNA in supernatant fluid from the same biliary brushings. Preservative supernatant fluid that normally is discarded was simply decanted after cytocentrifugation of cells and reserved for MP testing, whereas the corresponding cell pellets underwent cytology or FISH testing.
Our results confirm the ability of FISH aneuploidy to improve detection of malignancy when used in combination with routine cytology. 9, 13, 27 We also confirm the additional benefit of FISH 9p21 (p16) deletion testing in the detection of malignancy. 8 However, the combination of FISH p16 and routine cytology still only detected 51% of malignant strictures in our cohort.
Because both of these modalities rely on identification of neoplastic cells, we hypothesized that PCR-based MP testing of normally discarded supernatant fluid containing free DNA could increase the ability to rule-in malignancy. The sensitivity of MP alone was not significantly different than cytology, but in combination with cytology a significantly higher number of malignancies were identified, similar to observations of others in smaller studies. [14] [15] [16] 28 The combination of routine cytology and MP testing had comparable sensitivity for malignancy with that of combined routine cytology and FISH p16 testing (both 51%) in the same patients. However, the combination of all 3 test results (cytology, FISH p16 , and MP) had the highest sensitivity (73%) and specificity (100%) for malignancy. Other investigators have reported improved detection of malignancy in biliary strictures when a combination of cytology, FISH, and PCR-based KRAS mutation testing is performed. 10 In our cohort, examining tumor-suppressor gene LOH mutations enhanced detection of malignancy beyond that achieved by KRAS oncogene mutation testing alone. Tumor-suppressor LOH mutation was solely responsible for detecting malignancy in nearly half of all cases deemed positive by MP. Most notably, MP and FISH testing appeared complementary to one another, identifying a nonoverlapping set of 17 malignant cases otherwise undetectable by cytology.
Our study had certain limitations that may have impacted generalized conclusions. A somewhat higher benign stricture rate was noted in our cases than in other prior series. 8 There also were relatively few PSC patients included in this study. Prior studies have shown that there is a significant aneuploidy rate associated with premalignant lesions seen in PSC. 29, 30 Because of this, specificity of FISH for malignancy is expected to be lower in a cohort of PSC patients than we reported in our cohort. Less is known about detection of KRAS mutations in the progression of PSC to cholangiocarcinoma. However, based on our study cohort and prior studies, our results likely are not generalizable to the PSC population.
Our results support the use of both FISH testing and PCR-based MP of tumor-suppressor gene LOH and KRAS in evaluation of cytology-negative or indeterminate biliary strictures. MP allows for increased diagnostic yield from each individual brush, given that normally discarded, cell-free supernatant material that contains DNA can be analyzed. Based on our results, we suggest using either FISH or MP as a second-line diagnostic modality to first-line cytology. MP may be best prioritized to scenarios of low cellularity. Any case that is negative or indeterminate by 2 testing modalities should undergo a third to increase the probability of detecting possible malignancy. To do so, normally discarded supernatant fluid should be retained for MP testing during the standard cytology cytocentrifugation preparation of cells for cytology. Additional studies may help to better understand the reflex order of sequential testing and the impact of this reflex on health economics.
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